Inventor · disambiguated record
Remko Alexander Bakker
Also filed as: BAKKER REMKO · BAKKER REMKO ALEXANDER
8 granted patents·6 pending applications·15 citations·filing 2011–2024
79Inventor score
Top patents by PatentIndex Score
14 records- 0186US10640486B2Heteroarylcarboxamide derivatives as plasma kallikrein inhibitorsBOEHRINGER INGELHEIM INT·Filed 2016·Granted May 5, 2020·4 cites·13 claims
- 0283US10501440B2Heteroarylcarboxamide derivatives as plasma kallikrein inhibitorsBOEHRINGER INGELHEIM INT·Filed 2018·Granted Dec 10, 2019·4 cites·14 claims
- 0382US10399961B2Heteroarylcarboxamide derivatives as plasma kallikrein inhibitorsBOEHRINGER INGELHEIM INT·Filed 2016·Granted Sep 3, 2019·4 cites·12 claims
- 0479US10793634B2Anti-TrkB antibodiesBOEHRINGER INGELHEIM INT·Filed 2018·Granted Oct 6, 2020·3 cites·38 claims
- 0578US2024228600A1Anti-sema3a antibodies and their uses for treating a thrombotic disease of the retinaBOEHRINGER INGELHEIM INT·Filed 2023·Application pending·0 cites
- 0674US2025051460A1Bispecific anti-vegf and anti-trkb binding molecules for the treatment of eye diseasesBOEHRINGER INGELHEIM INT·Filed 2024·Application pending·0 cites
- 0774US2024101689A1Anti-trkb antibodiesBOEHRINGER INGELHEIM INT·Filed 2023·Application pending·0 cites
- 0869US2022127344A1Anti-sema3a antibodies and their uses for treating a thrombotic disease of the retinaBOEHRINGER INGELHEIM INT·Filed 2021·Application pending·0 cites
- 0964US12110335B2Bispecific anti-VEGF and anti-TrkB binding molecules for the treatment of eye diseasesBOEHRINGER INGELHEIM INT·Filed 2021·Granted Oct 8, 2024·0 cites·15 claims
- 1062US11866501B2Anti-TrkB antibodiesBOEHRINGER INGELHEIM INT·Filed 2020·Granted Jan 9, 2024·0 cites·1 claims
- 1158US10603292B2Pharmaceutical composition and pharmaceutical dosage form comprising (E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide, process for their preparation, methods for treating and uses thereofBOEHRINGER INGELHEIM INT·Filed 2018·Granted Mar 31, 2020·0 cites·13 claims
- 1247US2020188337A1Pharmaceutical composition and pharmaceutical dosage form comprising (E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide, process for their preparation, methods for treating and uses thereofBOEHRINGER INGELHEIM INT·Filed 2020·Application pending·0 cites
- 1340US2012302566A1Indanyloxydihydrobenzofuranylacetic acidsHIMMELSBACH FRANK·Filed 2011·Application pending·0 cites
- 1437US8772323B2Benzoxazole- and tetrahydrobenzoxazole-substituted pyridazinones as GPR119 agonistsGRAUERT MATTHIAS·Filed 2011·Granted Jul 8, 2014·0 cites·11 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →